A pharmaceutical combination for the treatment of lung infections in subjects with cystic fibrosis

The present invention relates to a combination therapy for treating infections caused by Mycobacterium abscessus and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulators.